Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

Ilaria Cuomo, Georgios D Kotzalidis, Simone de Persis, Daria Piacentino, Filippo Perrini, Emanuela Amici, Sergio De Filippis
  • June 2018, Dove Medical Press
  • DOI: 10.2147/ndt.s171002

Once-monthly aripiprazole and paliperidone comparison

What is it about?

Aripiprazole and paliperidone once-monthly formulations were equally effective in reducing psychosis in patients with comorbid psychosis and substance use disorder, but aripiprazole reduced craving and improved quality of life more than paliperidone.

Why is it important?

In cases of comorbidity with substance use disorders, patients with psychosis fare better on craving and quality of life on aripiprazole once-monthly; hence, the latter should be preferred in such cases.

Perspectives

Dr Georgios D. Kotzalidis (Author)
Sapienza University, NESMOS Department

Aripiprazole may be compared on the above outcomes with other long-acting formulations to define whether it's a choice treatment in comorbid psychosis (schizophrenia, schizoaffective disorder, and psychotic bipolar disorder) and substance use disorder.

open access logoRead Publication

http://dx.doi.org/10.2147/ndt.s171002

The following have contributed to this page: Dr Georgios D. Kotzalidis and emanuela amici